Clinical Trial

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.
Protocol Amendment History 6 changes
critical Primary endpoint(s) modified 2026-06-02
notable Enrollment increased: 132 -> 381 participants 2026-06-02
notable Sponsor changed: Metsera, a wholly owned subsidiary of Pfizer -> Pfizer 2026-06-02
minor Trial arms changed: 5 -> 6 2026-06-02
notable Primary completion moved earlier: 2027-01-25 -> 2026-09-15 2026-06-02
minor Completion moved earlier: 2027-03-15 -> 2026-09-15 2026-06-02
Trial Details
NCT Number NCT06924320
Lead Sponsor Pfizer
Conditions Obesity and Obesity-related Medical Conditions
Enrollment 381 participants
Start Date 2025-03-06
Primary Completion 2026-09-15 (estimated)
Study Completion 2026-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-01